OBJECTIVE: To evaluate whether the addition of exercise to a very low calorie diet (VLCD) has beneficial short- and long-term effects on health-related quality of life (QoL) in obese patients with type 2 diabetes mellitus (T2DM). METHODS: We included 27 obese, insulin-dependent T2DM patients in a 16-week VLCD study, of whom 13 participated simultaneously in anexercise program (VLCD+E). Before, immediately after and 18 months after the intervention anthropometric measurements, glucoregulation and QoL (SF-36, HADS, NHP and MFI-20) were assessed. Patients were compared to healthy lean and obese (matched for body mass index) controls matched for gender and age. RESULTS: At baseline, T2DM patients had significantly worse QoL scores in 18 and 14 of the 22 subscales of the QoL questionnaires, compared to lean and obese controls, resp. The 16-week VLCD (n=27) decreased bodyweight (-25.4±1.3 kg, p<0.0001, p=0.179 between groups), and improved glucoregulation (HbA1c -1.3±0.3%, p<0.0001, p=0.488 between groups) and 9 (VLCD-only) and 11 (VLCD+E) of the 22 subscales of QoL. After 18 months, in the VLCD+E group the QoL subscales did not differ from those in obese controls and only 4 of the 22 subscales were significantly worse compared to lean controls. However, in the VLCD-only group 17 and 13 of the 22 QoL subscales were significantly worse compared to the lean and obese controls, resp. CONCLUSION: A 16-week VLCD induces considerable weight loss, metabolic amelioration, and major improvements in QoL in obese T2DM patients. The addition of exercise is of paramount importance for the maintenance of better QoL.
RCT Entities:
OBJECTIVE: To evaluate whether the addition of exercise to a very low calorie diet (VLCD) has beneficial short- and long-term effects on health-related quality of life (QoL) in obesepatients with type 2 diabetes mellitus (T2DM). METHODS: We included 27 obese, insulin-dependent T2DM patients in a 16-week VLCD study, of whom 13 participated simultaneously in an exercise program (VLCD+E). Before, immediately after and 18 months after the intervention anthropometric measurements, glucoregulation and QoL (SF-36, HADS, NHP and MFI-20) were assessed. Patients were compared to healthy lean and obese (matched for body mass index) controls matched for gender and age. RESULTS: At baseline, T2DM patients had significantly worse QoL scores in 18 and 14 of the 22 subscales of the QoL questionnaires, compared to lean and obese controls, resp. The 16-week VLCD (n=27) decreased bodyweight (-25.4±1.3 kg, p<0.0001, p=0.179 between groups), and improved glucoregulation (HbA1c -1.3±0.3%, p<0.0001, p=0.488 between groups) and 9 (VLCD-only) and 11 (VLCD+E) of the 22 subscales of QoL. After 18 months, in the VLCD+E group the QoL subscales did not differ from those in obese controls and only 4 of the 22 subscales were significantly worse compared to lean controls. However, in the VLCD-only group 17 and 13 of the 22 QoL subscales were significantly worse compared to the lean and obese controls, resp. CONCLUSION: A 16-week VLCD induces considerable weight loss, metabolic amelioration, and major improvements in QoL in obese T2DM patients. The addition of exercise is of paramount importance for the maintenance of better QoL.
Authors: A Khader; G Ballout; Y Shahin; M Hababeh; L Farajallah; W Zeidan; I Abu-Zayed; A Kochi; A D Harries; R Zachariah; A Kapur; I Shaikh; A Seita Journal: Public Health Action Date: 2013-12-21
Authors: Daniel J van den Hoek; Clint T Miller; Steve F Fraser; Steve E Selig; John B Dixon Journal: Qual Life Res Date: 2017-05-27 Impact factor: 4.147
Authors: Seyede Hamide Rajaie; Sepideh Soltani; Zeinab Yazdanpanah; Tayebeh Zohrabi; Sara Beigrezaei; Sahar Mohseni-Takalloo; Mojtaba Kaviani; Scott C Forbes; Julien S Baker; Amin Salehi-Abargouei Journal: Qual Life Res Date: 2022-05-06 Impact factor: 3.440
Authors: Maria A Sleddering; Albert J Markvoort; Harish K Dharuri; Skhandhan Jeyakar; Marieke Snel; Peter Juhasz; Moira Lynch; Wade Hines; Xiaohong Li; Ingrid M Jazet; Aram Adourian; Peter A J Hilbers; Johannes W A Smit; Ko Willems Van Dijk Journal: PLoS One Date: 2014-11-21 Impact factor: 3.240
Authors: Charmi A Patel; Robert A Bailey; Ujjwala Vijapurkar; Gary Meininger; Lawrence Blonde Journal: BMC Health Serv Res Date: 2016-08-05 Impact factor: 2.655
Authors: A Goday; D Bellido; I Sajoux; A B Crujeiras; B Burguera; P P García-Luna; A Oleaga; B Moreno; F F Casanueva Journal: Nutr Diabetes Date: 2016-09-19 Impact factor: 5.097